Pfizer to Present More Than 50 Infectious Disease Abstracts at IDWeek 2026
Pfizer will present data from more than 50 abstracts, including company-led, investigator-led, and collaborative studies, at IDWeek 2026 in Washington, D.C., from October 21 to 24. Twelve oral presentations will cover advances in preventing and treating infectious diseases across its pipeline and portfolio. Pfizer says the work addresses urgent challenges in infectious diseases.
Pfizer will bring findings from over fifty infectious disease abstracts to IDWeek 2026. The conference takes place in Washington, D.C., from October 21 through 24. The work includes studies run by Pfizer, studies led by outside investigators, and partnership-based research, covering the company’s infectious disease development efforts and existing products.
Twelve oral presentations will focus on progress in preventing and treating infections. Pfizer says these efforts target urgent infectious disease challenges. The company trades on the New York Stock Exchange under PFE.
The data shared at IDWeek 2026 could inform how clinicians, public health teams, and patients approach infectious disease prevention and care. If findings support new or improved options, they may influence treatment decisions, vaccine uptake, and outbreak preparedness. People at higher risk of infection, including older adults and those with weakened immune systems, could benefit most. However, conference abstracts often represent early results, so real-world impact may depend on peer review, regulatory review, and access.